Effect of Acid Suppression Medication on Pediatric Microbiome

Status Terminated

Clinical Trial Summary

The colonic microbiome is essential in health and disease, and is highly dynamic during the first several years of life. Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely used in children, but the effects of PPIs and H2RAs on the pediatric colonic microbiome are unknown. This study will determine whether acid suppression with these medications affects the microbiome of otherwise healthy children who are prescribed acid suppression for gastroesophageal reflux disease (GERD), and determine the duration and magnitude of microbiome changes.

Clinical Trial Description

Otherwise healthy children age 0-4 years old who are being considered for acid suppressive therapy for GERD will be eligible for this study. Subjects donate samples before and after being treated with PPIs or H2RAs (must donate at least 2 baseline pre-PPI samples to be eligible for final analysis). 30 total children who complete the study (anticipated 10 who receive lifestyle modification and 20 who receive PPIs or H2RAs). All children will donate 6 stools on or about weeks 0, 4, 12, 20, 38, and 64. The primary outcome will be a significant change in the overall diversity of the colonic microbiome after 8 weeks of PPIs or H2RAs (i.e., from week 12 to week 4), compared to after 4 weeks of lifestyle management. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02016820
Study type	Interventional
Source	Columbia University
Contact
Status	Terminated
Phase	N/A
Start date	November 2014
Completion date	January 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02214771` - Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients	N/A
Withdrawn	`NCT01552668` - Fidaxomicin to Prevent Clostridium Difficile Colonization	Phase 4
Recruiting	`NCT03325855` - Fecal Microbiota Transplant National Registry
Not yet recruiting	`NCT03586206` - Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
Suspended	`NCT03350711` - A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
Withdrawn	`NCT03643887` - Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients	Phase 2
Terminated	`NCT04000555` - Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)	Phase 4
Terminated	`NCT03065374` - Treatment for Clostridium-difficile Infection With IMM529	Phase 1/Phase 2
Completed	`NCT03710694` - Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)	N/A
Completed	`NCT02865616` - MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)	Phase 1
Recruiting	`NCT04940468` - High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology	N/A
Completed	`NCT02589847` - Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	Phase 2
Not yet recruiting	`NCT01942447` - Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis	N/A
Active, not recruiting	`NCT02086916` - Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection	N/A
Completed	`NCT01230957` - Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults	Phase 2
Completed	`NCT01241552` - A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)	Phase 3
Not yet recruiting	`NCT04567134` - Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea
Completed	`NCT04075422` - Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
Recruiting	`NCT03712722` - Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Recruiting	`NCT05192148` - Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile	N/A